428 related articles for article (PubMed ID: 22272301)
1. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
4. Intracrine androgen biosynthesis in renal cell carcinoma.
Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
[TBL] [Abstract][Full Text] [Related]
5. Castration-recurrent prostate cancer is not androgen-independent.
Mohler JL
Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
[TBL] [Abstract][Full Text] [Related]
6. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
[TBL] [Abstract][Full Text] [Related]
9. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
10. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
11. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
13. Androgen regulation of micro-RNAs in prostate cancer.
Waltering KK; Porkka KP; Jalava SE; Urbanucci A; Kohonen PJ; Latonen LM; Kallioniemi OP; Jenster G; Visakorpi T
Prostate; 2011 May; 71(6):604-14. PubMed ID: 20945501
[TBL] [Abstract][Full Text] [Related]
14. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
Simanainen U; McNamara K; Gao YR; Handelsman DJ
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
[TBL] [Abstract][Full Text] [Related]
15. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
16. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
17. Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.
Wu Y; Tang L; Azabdaftari G; Pop E; Smith GJ
Mol Cell Endocrinol; 2019 Apr; 486():79-88. PubMed ID: 30807787
[TBL] [Abstract][Full Text] [Related]
18. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ
Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501
[TBL] [Abstract][Full Text] [Related]
19. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
Ribas J; Ni X; Haffner M; Wentzel EA; Salmasi AH; Chowdhury WH; Kudrolli TA; Yegnasubramanian S; Luo J; Rodriguez R; Mendell JT; Lupold SE
Cancer Res; 2009 Sep; 69(18):7165-9. PubMed ID: 19738047
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
